National Bank of Canada
ADMA icon

National Bank of Canada’s ADMA Biologics ADMA Stock Holding History

National Bank of Canada’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,748
Closed -$34.9K – 2914
2024
Q3 		$34.9K Buy
+1,748
New +$27.2K ﹤0.01% 1808

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

National Bank of Canada's ADMA Position: Q4 2024 in Review

National Bank of Canada sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 1,748 shares — an estimated $34.9K sold.

National Bank of Canada first reported a position in ADMA in Q3 2024 and held it in 1 quarter. The position peaked at $34.9K in Q3 2024. 321 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • National Bank of Canada reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 1,748 ADMA Biologics shares in Q4 2024, an estimated $34.9K.
  • National Bank of Canada first reported a position in ADMA Biologics in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's ADMA Biologics position peaked at $34.9K in Q3 2024.
  • 321 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.